WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 205486
Description: HQK-1004 is a bioactive chemical.
MedKoo Cat#: 205486
HQK-1004 is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to email@example.com to inquire quote.
Synonym: HQK1004; HQK 1004; HQK-1004; SCFA HQK1004; SCFA HQK 1004; SCFA HQK-1004
IUPAC/Chemical Name: NONE
The following data is based on the product molecular weight Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
HQK-1004 acts by inducing the expression of a gene for a viral protein that is the target of several common anti-viral drugs, including GCV, which eradicate virally infected cells. The gene that makes this target protein is present in EBV infected tumor cells, but it is not expressed, thus rendering these cells resistant to anti-viral therapeutics. To overcome this problem, HemaQuest has developed a proprietary therapeutic approach using HQK-1004, which enables the expression of the viral protein that is the target of anti-viral drugs. Combining HQK-1004 with anti-viral therapeutics now enables the killing of viral-infected tumor cells, while uninfected cells should not be affected.